ONC (BeOne Medicines) Other Current Assets: $180 Mil (As of Mar. 2026)


ONC BeOne Medicines Ltd ONC
79 GF Score
Price $302.83
GF Value $367.92
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is BeOne Medicines Other Current Assets?

BeOne Medicines ONC +0.31% 79 Other Current Assets is $180 Mil as of Mar. 2026. GuruFocus rates ONC with a GF Score™ of 79/100 and a GF Value™ of $367.92 (Modestly Undervalued). The stock has 4 warning signs investors should review.

BeOne Medicines's other current assets for the quarter that ended in Mar. 2026 was $180 Mil.

BeOne Medicines's quarterly other current assets declined from Sep. 2025 ($194 Mil) to Dec. 2025 ($191 Mil) and declined from Dec. 2025 ($191 Mil) to Mar. 2026 ($180Mil).

BeOne Medicines's annual other current assets declined from Dec. 2023 ($220 Mil) to Dec. 2024 ($160 Mil) increased from Dec. 2024 ($160 Mil) to Dec. 2025 ($191 Mil).


BeOne Medicines Other Current Assets Related Terms


BeOne Medicines Other Current Assets Historical Data

* Premium members only.

The historical data trend for BeOne Medicines's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeOne Medicines Other Current Assets Chart

BeOne Medicines Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 253.44 190.93 219.61 160.09 190.97

BeOne Medicines Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 139.44 171.17 193.54 190.97 179.65
ONC
79GF Score
BeOne Medicines Ltd ONC
Other Current Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeOne Medicines Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $180 Mil mean?
BeOne Medicines (ONC) has a Other Current Assets of $180 Mil as of Mar. 2026. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on BeOne Medicines.
Is BeOne Medicines' Other Current Assets too high?
BeOne Medicines' current Other Current Assets is $180 Mil. Overall, BeOne Medicines has a GF Score™ of 79/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Other Current Assets compare to MRNA and RPRX?
BeOne Medicines' Other Current Assets of $180 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on BeOne Medicines. BeOne Medicines's current Other Current Assets is $180 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (ONC) is currently considered Modestly Undervalued. The stock's GF Value™ is $367.92, compared to a current price of $302.83 — trading 17.7% below its estimated fair value. The current Other Current Assets is $180 Mil. BeOne Medicines' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For BeOne Medicines (ONC), the current Other Current Assets is $180 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BeOne Medicines (ONC) Overvalued in 2026?

Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued. The current stock price of $302.83 is trading 17.7% below its estimated GF Value™ of $367.92. GuruFocus considers BeOne Medicines to be Modestly Undervalued.

Key valuation signals for ONC:

  • Other Current Assets: $180 Mil
  • GF Value™: $367.92 vs. price of $302.83 (17.7% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the ONC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BeOne Medicines Business Description

Address c/o BeOne Medicines I GmbH, 94 Aeschengraben 27, 21st Floor, Basel, CHE, 4051
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
79GF Score

Get the complete analysis for ONC

Other Current Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$302.83
Price
$367.92
GF Value